RLD identification in EU region in view of Brexit [Regulatives / Guidelines]

posted by shahajan baig  – India, 2021-08-31 14:49 (23 d 20:19 ago) – Posting: # 22556
Views: 550

Dear Member,

Hope everyone is safe and healthy in this pandemic situation.

I wanted to know about RLD identification & selection in EU region since we do not have any specific source like in USFDA which provides the orange book data or OGD guidance. Also, we don't have several product-specific guidance in EU regions. Ao in such conditions how can we identify & select RLD in EU region? Also please guide me about how Brexit impacted DCP and CP in EU union for the selection of RLD.

A response will be highly appreciated

Regards,

SHAHAJAN BAIG

Complete thread:

Activity
 Admin contact
21,693 posts in 4,535 threads, 1,541 registered users;
online 5 (1 registered, 4 guests [including 3 identified bots]).
Forum time: Friday 11:09 CEST (Europe/Vienna)

Tortured data will confess to anything.    Fredric Menger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5